Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Consolidated Net Income: 2019-2024

Historic Consolidated Net Income for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to -$86.6 million.

  • Foghorn Therapeutics' Consolidated Net Income rose 13.87% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.0 million, marking a year-over-year increase of 17.80%. This contributed to the annual value of -$86.6 million for FY2024, which is 11.99% up from last year.
  • According to the latest figures from FY2024, Foghorn Therapeutics' Consolidated Net Income is -$86.6 million, which was up 11.99% from -$98.4 million recorded in FY2023.
  • Over the past 5 years, Foghorn Therapeutics' Consolidated Net Income peaked at -$69.5 million during FY2020, and registered a low of -$108.9 million during FY2022.
  • In the last 3 years, Foghorn Therapeutics' Consolidated Net Income had a median value of -$98.4 million in 2023 and averaged -$98.0 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first plummeted by 47.58% in 2021, then grew by 11.99% in 2024.
  • Yearly analysis of 5 years shows Foghorn Therapeutics' Consolidated Net Income stood at -$69.5 million in 2020, then crashed by 47.58% to -$102.6 million in 2021, then declined by 6.14% to -$108.9 million in 2022, then increased by 9.60% to -$98.4 million in 2023, then grew by 11.99% to -$86.6 million in 2024.